Interdisciplinary Perspectives on Infectious Diseases / 2021 / Article / Tab 2 / Research Article
Efficacy of Colchicine and Budesonide in Improvement Outcomes of Patients with Coronavirus Infection 2019 in Damascus, Syria: A Randomized Control Trial Table 2 Admission criteria, laboratories, and additional supportive treatments.
Laboratory characteristics Supportive Colchicine Budesonide valueAdmission criteria sat ≤ 93% + 1 condition 4 4 0 0.11 sat ≤ 93% + 2 conditions 9 4 6 0.69 sat ≤ 93% + 3 conditions 8 6 8 0.70 WBCs (white blood cells) ≤10th/ml 8 7 7 0.70 10–20th/ml 13 7 4 0.21 ≥20th/ml 0 0 3 0.01 Lymphocytes ≤5% 9 1 5 0.05 5–10% 6 6 4 0.36 10–20% 6 6 4 0.62 ≥20% 0 1 1 0.46 HB (hemoglobin) ≤10 g/dl 6 4 1 0.26 10–13 g/dl 9 5 10 0.12 ≥13 g/dl 6 5 3 0.87 PLT (platelets) <150th/ml 5 1 3 0.40 ≥150th/ml 16 13 11 0.40 Ur (urea) ≤45 mg/dl 8 6 5 0.02 45–100 mg/dl 6 5 5 0.87 ≥100 mg/dl 6 3 5 0.74 Cr (creatinine) 0.5–1.2 mg/dl 11 8 8 0.94 1.2–2 mg/dl 4 3 2 0.83 2–3 mg/dl 3 2 3 0.83 ≥3 mg/dl 3 1 1 0.78 ALT (alanine aminotransferase) ≤41 mg/dl 15 9 9 0.87 41–100 mg/dl 5 5 5 0.87 ≥100 mg/dl 1 0 0 0.51 AST (aspartate aminotransferase) ≤38 mg/dl 11 5 6 0.61 38–100 mg/dl 8 9 7 0.31 ≥100 mg/dl 2 0 1 0.44 CK (creatine kinase) ≤170 mg/dl 17 9 12 0.35 170–500 mg/dl 4 4 0 0.11 ≥500 mg/dl 0 1 2 0.27 LDH (lactate dehydrogenase) ≤480 mg/dl 5 0 1 0.08 480–1000 mg/dl 9 8 10 0.25 ≥1000 mg/dl 7 6 3 0.48 PT (prothrombin time) <60% 4 0 3 0.19 ≥60% 17 14 11 0.19 INR (international normalized ratio) ≤1.2 16 12 10 0.65 >1.2 5 2 4 0.65 CRP (C-reactive protein) ≤0.5 ـــــ ـــــ ـــــ ـــــ 0.5–10 9 9 5 0.28 10–20 7 4 5 0.91 ≥20 5 1 4 0.08 Pro-CT (procalcitonin) <0.1 8 5 5 0.27 0.1–0.5 8 7 5 0.70 ≥0.5 5 2 4 0.65 D-dimer <1000 12 8 4 0.19 ≥1000 9 6 10 0.19 Crcl (creatinine clearance) ≥90 7 5 5 0.96 90–60 4 5 4 0.53 60–30 6 3 3 0.84 <30 4 1 2 0.17 Antibiotic Azithro 3 3 1 0.36 Azithro + ceftriaxone 11 7 6 0.85 Levofloxacin 6 4 6 0.63 Others 1 0 1 0.62 Padua score <4 ـــــ ـــــ ـــــ ـــــ ≥4 21 14 14 1 Anticoagulants Enoxaparin 40 mg/d 9 5 6 0.90 Apixaban 2.5 mg/twice/d 3 3 1 0.56 Apixaban 5 mg/twice/d 9 6 7 0.93 Other drugs 10 6 4 0.52 Complications of COVID-19 6 4 6 0.62